Dover Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-12-2024
- Paid Up Capital ₹ 0.10 M
as on 11-12-2024
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 20.00 Cr
as on 11-12-2024
- Revenue %
(FY 2022)
- Profit -26.56%
(FY 2022)
- Ebitda -26.56%
(FY 2022)
- Net Worth -56.06%
(FY 2022)
- Total Assets -6.35%
(FY 2022)
About Dover Pharmaceuticals
The Company is engaged in the Energy And Power Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹20.00 Cr.
Sabah Kamal, Sara Kamal, and Sanah Kamal serve as directors at the Company.
- CIN/LLPIN
U40100KA2015PTC083584
- Company No.
083584
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Oct 2015
- Date of AGM
13 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- LocationBengaluru, Karnataka
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dover Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sabah Kamal  | Director | 24-Aug-2022 | Current |
| Sara Kamal | Director | 30-Jul-2018 | Current |
| Sanah Kamal | Director | 24-Aug-2022 | Current |
Financial Performance of Dover Pharmaceuticals.
Dover Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 26.56% decrease in profit. The company's net worth observed a substantial decline by a decrease of 56.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dover Pharmaceuticals?
In 2022, Dover Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Applied Solar Power Management Private LimitedActive 13 years 3 monthsSanah Kamal is a mutual person
Hiriyur Farms Private LimitedActive 6 years 12 daysSabah Kamal, Sara Kamal and 1 more are mutual person
- Sira Agro Industries Private LimitedActive 5 years 10 months
Sara Kamal and Sanah Kamal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Aug 2024 | ₹20.00 Cr | Open |
How Many Employees Work at Dover Pharmaceuticals?
Unlock and access historical data on people associated with Dover Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dover Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dover Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
